Shares of Teleflex Incorporated (NYSE:TFX – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $162.41 and last traded at $161.3690, with a volume of 24,810 shares traded. The stock had previously closed at $159.55.
Analysts Set New Price Targets
Several analysts have weighed in on TFX shares. Royal Bank Of Canada boosted their price target on Teleflex from $155.00 to $175.00 and gave the company an “outperform” rating in a research note on Friday, November 6th. Truist Financial increased their price objective on Teleflex from $142.00 to $167.00 and gave the company a “hold” rating in a report on Monday, November 9th. Bank of America upgraded Teleflex from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $145.00 to $158.00 in a research note on Monday, September 28th. Wells Fargo & Company lifted their target price on Teleflex from $138.00 to $167.00 and gave the stock an “equal weight” rating in a report on Friday, November 6th. Finally, Mizuho set a $160.00 target price on Teleflex in a research report on Friday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Teleflex currently has a consensus rating of “Moderate Buy” and an average target price of $163.30.
Get Our Latest Report on Teleflex
Teleflex Stock Up 2.5%
The company has a market capitalization of $6.49 billion, a price-to-earnings ratio of 19.88, a P/E/G ratio of 1.05 and a beta of 0.85. The business’s 50-day moving average is $134.43 and its 200-day moving average is $127.90. The company has a quick ratio of 1.59, a current ratio of 2.01 and a debt-to-equity ratio of 0.44.
Teleflex (NYSE:TFX – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The medical technology company reported $2.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.90 by $0.73. Teleflex had a return on equity of 10.57% and a net margin of 13.51%. The business had revenue of $567.80 million during the quarter, compared to analysts’ expectations of $565.52 million. During the same quarter in the previous year, the firm posted $3.67 EPS. The company’s revenue for the quarter was up .1% on a year-over-year basis. As a group, equities analysts predict that Teleflex Incorporated will post 7.67 earnings per share for the current year.
Teleflex Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Monday, November 16th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 0.8%. The ex-dividend date is Monday, November 16th. Teleflex’s dividend payout ratio is currently 16.52%.
Hedge Funds Weigh In On Teleflex
Several institutional investors have recently made changes to their positions in TFX. BlackRock Inc. purchased a new stake in shares of Teleflex during the second quarter worth about $688,537,000. Jupiter Topco LLC acquired a new position in shares of Teleflex during the 2nd quarter worth about $550,456,000. Irenic Capital Management LP purchased a new position in Teleflex in the 1st quarter valued at about $104,061,000. Pzena Investment Management LLC purchased a new position in Teleflex in the 2nd quarter valued at about $76,462,000. Finally, Bank of America Corp DE purchased a new position in Teleflex in the 2nd quarter valued at about $61,156,000. 95.62% of the stock is owned by hedge funds and other institutional investors.
Teleflex Company Profile
Teleflex is a global medical technology company that develops, manufactures and markets single-use medical devices used by healthcare professionals in hospitals and other care settings. Its products support a range of procedures, including vascular access, anesthesia, critical care, surgery, urology and emergency medicine. The company’s offerings include vascular and interventional access devices, catheters, airway management products, surgical instruments and other devices used in diagnostic and therapeutic procedures.
Further Reading
- Five stocks we like better than Teleflex
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
